- Immune-related adverse events2017 | Faculty of Medicine in Hradec Králové
- Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer2023 | Third Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Central Library of Charles University
- Clinical dilemma of lung cancer treatment with anti-PD-1 therapy (nivolumab) in the discovery of rheumatological problems with joint swelling - case report2020 | First Faculty of Medicine
- Principles and mechanisms of side effects of modern immunooncological therapy2022 | First Faculty of Medicine
- How to manage side effects of immunotherapy How to manage side effects of immunotherapy2020 | Faculty of Medicine in Hradec Králové
- Immunization and its role in prevention of infectious diseases in the Czech Republic2011 | Publication without faculty affiliation
- Nivolumab induced encephalopathy in a man with metastatic renal celll cancer: a case report2018 | Faculty of Medicine in Hradec Králové
- Nežádoucí účinky imunoterapie monoklonálními protilátkami proti CTLA-4 a PD-12016 | Publication without faculty affiliation
- Immunotherapy in the treatment of triple negative breast cancer2022 | First Faculty of Medicine
- Adverse effects of combination immunotherapy in renal cancer, lung cancer, and melanoma +12022 | Faculty of Medicine in Hradec Králové
- Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors2020 | Faculty of Medicine in Pilsen
- Endocrine complications of modern cancer therapy2016 | Faculty of Medicine in Hradec Králové
- Neurotoxicity and immunotherapy2020 | Publication without faculty affiliation
- Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study2019 | First Faculty of Medicine
- Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade2020 | Second Faculty of Medicine
- Gastrointestinal toxicity of systemic oncology immunotherapy2022 | First Faculty of Medicine, Central Library of Charles University
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial2014 | Third Faculty of Medicine
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study2018 | Second Faculty of Medicine